AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28644907 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-fasting group
Number of subjects: 101
Study 28644907 — intervention group
Group type: COMPARATOR
Intervention: Long-fasting group
Number of subjects: 101
Study 26188541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 40
Study 26188541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment in type 2 diabetes patients
Number of subjects: 40
Study 26188541 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (n = 44)
Number of subjects: 40
Study 23987302 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month telephone-based behavioral counseling intervention
Number of subjects: 0
Study 23987302 — intervention group
Group type: COMPARATOR
Intervention: Attention control nutrition education intervention
Number of subjects: 0
Study 23987302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine bioverification
Number of subjects: 0
Study 21488751 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) fast: 7 days at 0.5 mg/kg, then 1.2 mg/kg
Number of subjects: 181
Study 21488751 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) slow: 7 days each at 0.5 and 0.8 mg/kg, then 1.2 mg/kg
Number of subjects: 181
Study 21488751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 21488751 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) pooled
Number of subjects: 181
Study 21488751 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) slow
Number of subjects: 181
Study 21488751 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) fast
Number of subjects: 181
Study 20301983 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (three times a day) plus a reduced calorie diet (600 kcal/day deficit)
Number of subjects: 166
Study 20301983 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus a reduced calorie diet (600 kcal/day deficit)
Number of subjects: 166
Study 17196810 — intervention group
Group type: EXPERIMENTAL
Intervention: DE+O(3) exposure (1-h DE exposure at PM-concentration of 300 microg/m(3) followed by 2-h exposure to 0.2 ppm O(3))
Number of subjects: 0
Study 17196810 — intervention group
Group type: COMPARATOR
Intervention: DE+air exposure (1-h DE exposure at PM-concentration of 300 microg/m(3) followed by 2-h exposure to filtered air)
Number of subjects: 0
Study 15201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 166
Study 15201546 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 10-20 mg
Number of subjects: 166
Study 15201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 166
Study 15201546 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 166
Study 11345750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane alone (S group)
Number of subjects: 30
Study 11345750 — intervention group
Group type: COMPARATOR
Intervention: Propofol and sevoflurane (PS group)
Number of subjects: 30
Study 9154869 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation (IRV) (I/E = 2)
Number of subjects: 8
Study 9154869 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV) (I/E = 0.5)
Number of subjects: 8
Study 8431748 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoDERM E (DE)
Number of subjects: 60
Study 8431748 — intervention group
Group type: COMPARATOR
Intervention: scarlet red (SR)
Number of subjects: 60
Study 3116980 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (40 ng/kg/min; i.v.)
Number of subjects: 28
Study 3116980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 28
Study 3116980 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 and 20 ng/kg/min; i.v.)
Number of subjects: 28
Study 3116980 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 28
Study 31988225 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic LED-light
Number of subjects: 150
Study 31988225 — intervention group
Group type: COMPARATOR
Intervention: Static LED-light
Number of subjects: 150
Study 29845723 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 5 to 200 mg
Number of subjects: 60
Study 29845723 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 50 mg (Food Effect part)
Number of subjects: 60
Study 28126541 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel emergency contraceptive (1.5mg)
Number of subjects: 32
Study 28126541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate emergency contraceptive (30mg)
Number of subjects: 32
Study 27025129 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol at a dose of 800 mg/day for 7 days
Number of subjects: 44
Study 23910198 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical technique
Number of subjects: 62
Study 23910198 — intervention group
Group type: COMPARATOR
Intervention: Closed surgical technique
Number of subjects: 62
Study 23910198 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated canines (both techniques combined)
Number of subjects: 62
Study 23910198 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated canines
Number of subjects: 62
Study 21529363 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW (2 mg)
Number of subjects: 295
Study 18442484 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 65
Study 18442484 — intervention group
Group type: COMPARATOR
Intervention: Standard resolution endoscopy
Number of subjects: 65
Study 18442484 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band directed biopsies
Number of subjects: 65
Study 18442484 — intervention group
Group type: COMPARATOR
Intervention: Standard resolution endoscopy with random biopsy
Number of subjects: 65
Study 18442484 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band targeted biopsies
Number of subjects: 65
Study 17041074 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP)
Number of subjects: 0
Study 17041074 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 12207128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg piritramide intravenously (group A)
Number of subjects: 60
Study 12207128 — intervention group
Group type: COMPARATOR
Intervention: Normal saline intravenously (group B)
Number of subjects: 60
Study 10491673 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home prenatal nutrition intervention
Number of subjects: 40
Study 10491673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 8941514 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoxia training (HT); barometric pressure = 500 mmHg; inspired O2 fraction = 0.209
Number of subjects: 20
Study 8941514 — intervention group
Group type: COMPARATOR
Intervention: Acute normoxia training (NT); barometric pressure = 500 mmHg; inspired O2 fraction = 0.314
Number of subjects: 20
Study 1849152 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid (30 mL Maalox) with 500 mg azithromycin
Number of subjects: 22
Study 1849152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg) 2 hours before 500 mg azithromycin
Number of subjects: 22
Study 1849152 — intervention group
Group type: COMPARATOR
Intervention: Placebo before 500 mg azithromycin
Number of subjects: 22
Study 6639916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (MaxEPA), 10 g daily for 2 weeks
Number of subjects: 10
Study 6639916 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil supplement, 10 g daily for 2 weeks
Number of subjects: 10
Study 6639916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplements
Number of subjects: 10
Study 30237548 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH)
Number of subjects: 45
Study 30998693 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to media concerning facility delivery
Number of subjects: 420
Study 30998693 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) attendance less than 4 times
Number of subjects: 420
Study 30998693 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of first ANC visit in the 2nd and 3rd trimesters of pregnancy
Number of subjects: 420
Study 28272464 — intervention group
Group type: EXPERIMENTAL
Intervention: HF/HC diet
Number of subjects: 29
Study 28272464 — intervention group
Group type: COMPARATOR
Intervention: HC/HF diet
Number of subjects: 29
Study 25388552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education combined with exercise therapy (supervised exercises 3 times/week for 3 months)
Number of subjects: 121
Study 25388552 — intervention group
Group type: COMPARATOR
Intervention: Patient education alone
Number of subjects: 121
Study 25388552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education combined with exercise therapy
Number of subjects: 121
Study 24115345 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session body image programme
Number of subjects: 448
Study 24115345 — intervention group
Group type: COMPARATOR
Intervention: usual curriculum control
Number of subjects: 448
Study 21683609 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency sympathicolysis
Number of subjects: 58
Study 21683609 — intervention group
Group type: COMPARATOR
Intervention: Surgical sympathectomy
Number of subjects: 58
Study 19114437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (Group A)
Number of subjects: 35
Study 19114437 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 35
Study 16911633 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg on alternate days)
Number of subjects: 70
Study 16911633 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide (25 mg/kg daily)
Number of subjects: 70
Study 15298633 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 25
Study 15298633 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 25
Study 15298633 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 25
Study 11871864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 0
Study 11871864 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy
Number of subjects: 0
Study 9388818 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg body weight of rhGH
Number of subjects: 69
Study 9388818 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg body weight of rhGH
Number of subjects: 69
Study 9388818 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 69
Study 7716662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis
Number of subjects: 51
Study 7716662 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 51
Study 3330988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine/diuretic
Number of subjects: 71
Study 3330988 — intervention group
Group type: COMPARATOR
Intervention: Placebo/diuretic
Number of subjects: 71
Study 29464473 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sleep screening using Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)
Number of subjects: 281
Study 27608206 — intervention group
Group type: COMPARATOR
Intervention: Fractional microneedling radiofrequency (FMR) treatment on one side of the cheeks, two sessions with a 4-week interval.
Number of subjects: 0
Study 27608206 — intervention group
Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 0
Study 24372823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (F)
Number of subjects: 75
Study 24372823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish (CHX/T)
Number of subjects: 75
Study 24372823 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 75
Study 24002086 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (n=80)
Number of subjects: 113
Study 24002086 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline (n=33)
Number of subjects: 113
Study 20300033 — intervention group
Group type: COMPARATOR
Intervention: Method A (5 minutes of jogging)
Number of subjects: 26
Study 20300033 — intervention group
Group type: EXPERIMENTAL
Intervention: Method C (5 minutes of jogging and dynamic exercise)
Number of subjects: 26
Study 20300033 — intervention group
Group type: EXPERIMENTAL
Intervention: Method D (5 minutes of jogging and a combination of static stretching and dynamic exercise)
Number of subjects: 26
Study 19378580 — intervention group
Group type: EXPERIMENTAL
Intervention: Infragluteal sciatic nerve block (Group 1) with 30 mL of 0.5% bupivacaine (S75/R25) with 1:200,000 epinephrine
Number of subjects: 28
Study 19378580 — intervention group
Group type: COMPARATOR
Intervention: Parasacral sciatic nerve block (Group 2) with 30 mL of 0.5% bupivacaine (S75/R25) with 1:200,000 epinephrine
Number of subjects: 28
Study 16427366 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0
Study 16427366 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 15018685 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by an attractive female observer
Number of subjects: 4
Study 15018685 — intervention group
Group type: COMPARATOR
Intervention: Evaluation by an attractive male observer
Number of subjects: 4
Study 15018685 — intervention group
Group type: COMPARATOR
Intervention: No evaluation
Number of subjects: 4
Study 10958101 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol
Number of subjects: 80
Study 10958101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8630631 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 423
Study 8630631 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 423
Study 8630631 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg and Meloxicam 15 mg
Number of subjects: 423
Study 1465080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein intake (0.8‐1.1 g/kg/day)
Number of subjects: 200
Study 1465080 — intervention group
Group type: COMPARATOR
Intervention: Free protein intake (control group)
Number of subjects: 200
Study 1465080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (diet and control)
Number of subjects: 200
Study 434623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerium nitrate-silver sulfadiazine
Number of subjects: 34
Study 434623 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 34
Study 31235374 — intervention group
Group type: EXPERIMENTAL
Intervention: BBio bOPV
Number of subjects: 1080
Study 31235374 — intervention group
Group type: COMPARATOR
Intervention: SII bOPV
Number of subjects: 1080
Study 31235374 — intervention group
Group type: EXPERIMENTAL
Intervention: BBio bOPV (3 lots)
Number of subjects: 1080
Study 31235374 — intervention group
Group type: EXPERIMENTAL
Intervention: BBio bOPV and SII bOPV
Number of subjects: 1080
Study 27788625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge Preservation (RP) with freeze-dried bone allograft and non-resorbable dense polytetrafluoroethylene membrane
Number of subjects: 40
Study 27788625 — intervention group
Group type: COMPARATOR
Intervention: No Ridge Preservation (no RP)
Number of subjects: 40
Study 27788625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge Preservation (RP)
Number of subjects: 40
Study 26451096 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium/oxygen mixture (78%/22%)
Number of subjects: 30
Study 26451096 — intervention group
Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 30
Study 23076450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine combination therapy
Number of subjects: 1688
Study 23076450 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 150 mg
Number of subjects: 1688
Study 23076450 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 300 mg
Number of subjects: 1688
Study 23076450 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 1688
Study 23076450 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 1688
Study 21871978 — intervention group
Group type: EXPERIMENTAL
Intervention: INT reconstruction
Number of subjects: 103
Study 21871978 — intervention group
Group type: COMPARATOR
Intervention: RY reconstruction
Number of subjects: 103
Study 19207891 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg b.i.d. + surgery
Number of subjects: 70
Study 19207891 — intervention group
Group type: COMPARATOR
Intervention: Placebo + surgery
Number of subjects: 70
Study 17086096 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg/day with a maximum dose of 60 mg/day)
Number of subjects: 20
Study 16488417 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12825489 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor and psychological support
Number of subjects: 20
Study 12825489 — intervention group
Group type: COMPARATOR
Intervention: Transfer factor without psychological support
Number of subjects: 20
Study 12825489 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 20
Study 10434818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0
Study 10434818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 0
Study 7831493 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP system of nursing interventions
Number of subjects: 22
Study 7831493 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance from PREP nurses
Number of subjects: 22
Study 7831493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital costs for PREP group
Number of subjects: 22
Study 7831493 — intervention group
Group type: COMPARATOR
Intervention: Standard home health control group
Number of subjects: 22
Study 1977708 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 15
Study 1977708 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 15
Study 1977708 — intervention group
Group type: EXPERIMENTAL
Intervention: Befunolol
Number of subjects: 15
Study 530771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise at 840 kpm/min with pedalling rates of 40, 60, or 80 rpm.
Number of subjects: 50
Study 31472039 — intervention group
Group type: EXPERIMENTAL
Intervention: High circulating dipeptidyl peptidase 3 (cDPP3) group (cDPP3 ≥59.1 ng/mL) at inclusion
Number of subjects: 57
Study 31472039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid decrease in cDPP3 at 24 hours
Number of subjects: 57
Study 31472039 — intervention group
Group type: EXPERIMENTAL
Intervention: cDPP3 values measured at inclusion, 24h, 48h, and 72h
Number of subjects: 57
Study 31472039 — intervention group
Group type: EXPERIMENTAL
Intervention: cDPP3 at inclusion
Number of subjects: 57
Study 29600897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol (β1‐adrenergic receptor antagonist)
Number of subjects: 11
Study 29600897 — intervention group
Group type: COMPARATOR
Intervention: Volume‐matched saline (placebo)
Number of subjects: 11
Study 28721700 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR/amlodipine
Number of subjects: 197
Study 28721700 — intervention group
Group type: COMPARATOR
Intervention: Enalapril/amlodipine
Number of subjects: 197
Study 26613591 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 65
Study 26613591 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic volume (EDV)
Number of subjects: 65
Study 26613591 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 65
Study 26613591 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose metabolism and body composition measures
Number of subjects: 65
Study 24022033 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of Care (PoC) approach
Number of subjects: 346
Study 24022033 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 346
Study 21375416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated shears
Number of subjects: 200
Study 21375416 — intervention group
Group type: COMPARATOR
Intervention: Conventional clip and electrocautery
Number of subjects: 200
Study 18986282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibacterial drugs
Number of subjects: 7
Study 18986282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered antibacterial drugs
Number of subjects: 7
Study 15691522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (32% response rate)
Number of subjects: 20
Study 15691522 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (33% response rate)
Number of subjects: 20
Study 15691522 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 20)
Number of subjects: 20
Study 12924681 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging Moms Program
Number of subjects: 103
Study 12924681 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 103
Study 10390914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA) (1.5 mg/kg)
Number of subjects: 31
Study 10390914 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Sadamin, Partusisten, glucose i.v., amino acids i.v.)
Number of subjects: 31
Study 8686047 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria in rheumatoid arthritis patients
Number of subjects: 65
Study 8686047 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex and age matched)
Number of subjects: 65
Study 8686047 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of disease in patients with microalbuminuria
Number of subjects: 65
Study 8686047 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein correlation
Number of subjects: 65
Study 8686047 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with gold and penicillamine
Number of subjects: 65